Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-low Dose Naloxone for Remifentanil-Induced Hyperalgesia
NCT03066739Phase 2Terminated
- Sponsor
- University of California, Irvine
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of naloxone in hyperalgesia, sponsored by University of California, Irvine. Started Feb 2023; status: terminated.
02
Drugs
naloxone
03
Conditions
hyperalgesia
Beyond the preview
Go deeper on NCT03066739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066739.